eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.

© 2019 eviCore healthcare. All rights reserved.
<p>| PEDCD-1: General Guidelines                        | 3 |
| PEDCD-2: Congenital Heart Disease                | 9 |
| PEDCD-3: Heart Murmur                            | 14|
| PEDCD-4: Chest Pain                              | 16|
| PEDCD-5: Syncope                                 | 19|
| PEDCD-6: Kawasaki Disease                        | 22|
| PEDCD-7: Pediatric Pulmonary Hypertension        | 28|
| PEDCD-8: Echocardiography – Other Indications    | 31|
| PEDCD-9: Cardiac MRI – Other Indications         | 36|
| PEDCD-10: CT Heart and Coronary Computed Tomography Angiography (CCTA) – Other Indications | 41|
| PEDCD-11: Cardiac Catheterization                | 46|
| Procedure Codes Associated with Cardiac or PVD Imaging | 49|</p>
<table>
<thead>
<tr>
<th>PEDCD-1: General Guidelines</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PEDCD-1.1: Pediatric Cardiac Imaging Age Considerations</td>
<td>4</td>
</tr>
<tr>
<td>PEDCD-1.2: Pediatric Cardiac Imaging Appropriate Clinical Evaluation</td>
<td>4</td>
</tr>
<tr>
<td>PEDCD-1.3: Pediatric Cardiac Imaging Modality General Considerations</td>
<td>5</td>
</tr>
</tbody>
</table>
PEDCD-1.1: Pediatric Cardiac Imaging Age Considerations

- Heart disease in the pediatric population involves predominantly congenital lesions. Pediatric patients can have acquired heart disease unique to children. For those diseases which occur in both pediatric and adult populations, differences exist in management due to patient age, comorbidities, and differences in disease natural history between children and adults.

- Individuals who are < 18 years old should be imaged according to the Pediatric Cardiac Imaging Guidelines, and individuals who are age ≥ 18 years should be imaged according to the Cardiac Imaging Guidelines, except where directed otherwise by a specific guideline section.

PEDCD-1.2: Pediatric Cardiac Imaging Appropriate Clinical Evaluation

- A recent (within 60 days) face-to-face evaluation should be performed prior to considering advanced imaging unless the patient is undergoing guideline-supported scheduled follow-up imaging evaluation. This evaluation should include:
  - A detailed history
  - Physical examination
  - Appropriate laboratory studies

- Patients for whom routine imaging is anticipated at the next visit (for example on year follow-up echo for a 10 year old with a VSD) may have these imaging studies approved without face to face evaluation if study was already indicated

- Unless otherwise stated in a specific guideline section, the use of advanced imaging to screen asymptomatic patients for disorders involving the heart is not supported.

- Patients starting ADHD medications, in the absence of other appropriate indications listed in these guidelines, imaging is not indicated.

- Asymptomatic Patients with known or suspected syndromes, which may be associated with congenital heart disease, can have an initial echocardiogram.

- Asymptomatic patients with family history of aortopathy, cardiomyopathy, congenital heart disease with known inheritance pattern, can have an echocardiogram as an initial study. Additional studies are determined based on findings.

- Asymptomatic patients with exposure to cardiotoxic drugs can have serial echocardiograms as per PEDONC-19.2: Cardiotoxicity and Echocardiography

- Advanced imaging of the heart should only be approved in patients who have documented active clinical signs or symptoms of disease involving the heart or as follow-up for findings on echocardiograms.

- Unless otherwise stated in a specific guideline section, repeat imaging studies of the heart are not necessary unless:
  - There is evidence for progression of disease
  - New onset of disease and/or documentation of how repeat imaging will affect patient management or treatment decisions.
**PEDCD-1.3: Pediatric Cardiac Imaging Modality General Considerations**

- **MRI**
  - MRI and MRA studies are frequently indicated for evaluation of congenital heart defects not well visualized on echocardiography, thoracic arteries and veins not visualized on echocardiography, cardiomyopathies, and right ventricular disease, as well as in follow-up for these indications.
  - Due to the length of time for image acquisition and the need for the patient to be motionless during the acquisition, anesthesia is required for almost all infants and young children (age < 7 years), as well as older children with delays in development or maturity. In this patient population, MRI imaging sessions should be planned with a goal of avoiding a short-interval repeat anesthesia exposure due to insufficient information using the following considerations:
    - MRI is typically performed without and with contrast.
    - If multiple body areas are supported by eviCore guidelines for the clinical condition being evaluated, MRI of all necessary body areas should be obtained concurrently in the same anesthesia session.

- **CT**
  - CT is primarily used to evaluate the coronary and great vessels in congenital heart disease if cardiac MR is contraindicated.
  - Coding considerations are listed in **PEDCD-10: CT Heart and Coronary Computed Tomography Angiography (CCTA) – Other Indications**

- **Ultrasound**
  - Echocardiography is the primary modality used to evaluate the anatomy and function of the pediatric heart, and is generally indicated before considering other imaging modalities.
  - Coding considerations are listed in **PEDCD-8: Echocardiography Other Indications**.

- **Nuclear Medicine**

  **SPECT, PET stress** may be indicated for patients with anomalous CA, angina chest pain, and follow-up for Kawasaki. See specific sections for those indications.
  - Multi Gated Acquisition (MUGA) studies (CPT® 78472, CPT® 78473, CPT® 78481, CPT® 78483, CPT® 78494, or CPT® 78496) are rarely performed in pediatrics, but can be approved for the following:
    - Certain pediatric oncology patients when echocardiography is insufficient: See: **PEDONC-1.2: Appropriate Clinical Evaluations** for imaging guidelines.
    - Quantitation of left ventricular function when recent echocardiogram shows ejection fraction of < 50% and MUGA results will impact acute patient care decisions.
SPECT/CT fusion imaging involves SPECT (MPI) imaging and CT for optimizing location, accuracy, and attenuation correction combines functional and anatomic information.
- There is currently no evidence-based data to formulate appropriateness criteria for SPECT/CT fusion imaging.
- Combined use of nuclear imaging, including SPECT, along with diagnostic CT (fused SPECT/CT) is considered investigational.
- Central C-V Hemodynamics (CPT® 78414) is not an imaging study and is an outdated examination
- Cardiac Shunt Detection (CPT® 78428) is rarely performed in pediatrics but can be approved for patients in whom Cardiac MR is not diagnostic
  - Calculation of left and right ventricular ejection fractions
  - Assessment of wall motion
  - Quantitation of right to left shunts
- Myocardial Tc-99m Pyrophosphate Imaging
  - Infarct Avid Myocardial Imaging studies (CPT® 78466, CPT® 78468, and CPT® 78469), historically this method of imaging the myocardium, Myocardial Tc-99m Pyrophosphate Imaging, was used to identify recent infarction, hence, the term "infarct-avid scan." Although still available, the sensitivity and specificity for identifying infarcted myocardial tissue is variable and the current use for this indication is limited
  - CPT® 78466, CPT® 78468, and CPT® 78469, CPT® 78800 or CPT® 78803 may be used, for identification of myocardial ATTR (transthyretin) amyloidosis. Refer to CD-3.7: Myocardial Tc-99m Pyrophosphate Imaging and CD-3.8: Cardiac Amyloidosis

<table>
<thead>
<tr>
<th>MUGA (Multi Gated Acquisition) – Blood Pool Imaging</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial Imaging, infarct avid, planar, qualitative or quantitative</td>
<td>78466</td>
</tr>
<tr>
<td>Myocardial Imaging, infarct avid, planar, qualitative or quantitative with</td>
<td>78468</td>
</tr>
<tr>
<td>ejection fraction by first pass technique</td>
<td></td>
</tr>
<tr>
<td>Myocardial Imaging, infarct avid, planar, qualitative or quantitative</td>
<td>78469</td>
</tr>
<tr>
<td>tomographic SPECT with or without quantification</td>
<td></td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging Limited area</td>
<td>78800</td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging SPECT</td>
<td>78803</td>
</tr>
<tr>
<td>Note: When reporting CPT® 78803, planar imaging of a limited area or</td>
<td></td>
</tr>
<tr>
<td>multiple areas should be included with the SPECT</td>
<td></td>
</tr>
</tbody>
</table>

The guidelines listed in this section for certain specific indications are not intended to be all-inclusive; clinical judgment remains paramount and variance from these guidelines may be appropriate and warranted for specific clinical situations.
References


PEDCD-2: Congenital Heart Disease

| PEDCD-2.1: Congenital Heart Disease General Considerations | 10 |
| PEDCD-2.2: Congenital Heart Disease Echocardiography Coding | 10 |
| PEDCD-2.3: Congenital Heart Disease Modality Considerations | 10 |
| PEDCD-2.4: Congenital Heart Disease Timing Considerations | 11 |
PEDCD-2.1: Congenital Heart Disease General Considerations

- Congenital heart disease accounts for the majority of cardiac problems occurring in the pediatric population. Patients may be diagnosed any time spanning prenatal evaluation to adolescence. For patients over 18 year of age, see Adult Congenital Guidelines.

- There are a number of variables that influence the modality and timing of imaging patients with congenital heart disease, which results in a high degree of individuality in determining the schedule for imaging these patients, including:
  - Gestational age
  - Patient age
  - Physiologic effects of the defect
  - Status of interventions (catheterization and surgical)
  - Rate of patient growth
  - Stability of the defect on serial imaging
  - Comorbid conditions
  - Activity level

PEDCD-2.2: Congenital Heart Disease Echocardiography Coding

- Any of the following echocardiography code combinations are appropriate for re-evaluation of patients with known congenital heart disease:
  - CPT® 93303, CPT® 93320, and CPT® 93325
  - CPT® 93304, CPT® 93321, and CPT® 93325
  - CPT® 93303
  - CPT® 93304

- CPT® 93306 is not indicated in the evaluation of known congenital heart disease.

- All requested CPT® combinations other than those listed in this section should be forwarded for Medical Director Review.

PEDCD-2.3: Congenital Heart Disease Modality Considerations

- Echocardiography is the primary imaging modality used for diagnosing and monitoring congenital heart disease and is generally required before other imaging modalities are indicated unless otherwise indicated in a specific guideline section.

- Cardiac MRI either without contrast (CPT® 75557) or without and with contrast (CPT® 75561) is indicated, when a recent echocardiogram is inconclusive, needs confirmation of findings, or does not completely define the disease (for subsequent follow-up studies, a recent echocardiogram is not a requirement):
  - CPT® 75565 is also indicated for patients with valvular disease or a need to evaluate intracardiac blood flow. These patients will usually have CPT® 93320 and CPT® 93325 performed with their echocardiography studies.
  - MRA Chest (CPT® 71555) may be added if the aorta or pulmonary artery needs to be visualized beyond the root, or if aortopulmonary collaterals, pulmonary veins, or systemic veins need to be visualized.
MRA Chest alone (CPT® 71555) should be performed if the patient cannot cooperate with full cardiac MRI exam.

- MRA Chest (CPT® 71555) is assessment of the great arteries, pulmonary veins, and systemic chest veins, including the following:
  - Coarctation of the aorta, tetralogy of Fallot, anomalous pulmonary veins,
  - Transposition of the great arteries, Truncus arteriosus, vascular rings, and other lesions of the great arteries, with inconclusive recent echocardiography findings

- CT imaging is indicated, when recent echocardiogram is inconclusive, for the following:
  - Report CPT® 75574 for evaluating coronary artery anomalies
  - Report CPT® 75573 for congenital heart disease
  - CPT 71275 Determination of vascular extra-cardiac anatomy in patients with complex congenital heart disease
  - Pulmonary artery (PA) and Pulmonary vein (PV) assessment
  - CTA of the chest is indicated to assess, Coarctation of the aorta, tetralogy of Fallot, anomalous pulmonary veins, and other lesions of the great arteries, vascular rings, with inconclusive recent echocardiography findings

PEDCD-2.4: Congenital Heart Disease Timing Considerations

- Echocardiography is repeated frequently throughout a child’s life, and can generally be approved regardless of symptoms according to the following schedule, with some modifications listed below:
  - Patients 0-2 months:
    - Can have one repeat echocardiogram if prior echocardiogram is abnormal (either in hospital or as newborn outpatient)
  - Patient’s age 0 to 2 years:
    - every 3 months
    - Patients with single ventricle physiology (e.g., Hypoplastic left heart syndrome [HLHS], Mitral atresia, Unbalanced atrioventricular septal defect [uAVSD]) may require echocardiograms very frequently and can be approved:
      - Birth to 6 months of life: every 2 weeks
      - 7-12 months of life: 1 per month
      - Then every 3 months until 2 years of age
    - Patients with unrepaired asymptomatic isolated secundum atrial septal defect (ASD) without syndromes (such as Down Syndrome) or evidence of pulmonary hypertension:
      - Every 3 months until they are 1 year
      - Then once a year, unless consideration for surgery
  - Patient’s age 3 to 12 years:
    - Non-ASD patients: every 6 months
    - Patients with unrepaired asymptomatic isolated secundum atrial septal defect (ASD), without syndromes (such as Down Syndrome) or evidence of pulmonary hypertension:
      - Follow the above schedule until they are 1 year
Then they can have echocardiogram once a year, unless consideration for surgery.

- Patient’s age 13 years and older: every 12 months
- Modifiers to the above schedule:
  - Some congenital conditions may require more frequent testing, especially with more complex heart disease, congestive heart failure, obstructive heart lesions, ductal dependent lesions, changes in clinical status, repeat interventions, and/or in neonates
  - Any patient being treated for heart failure, with consideration for changing medical regimen can have an echocardiogram

> Echocardiography is performed during the physician office visit, and these studies should not be denied because of lack of contact within 60 days

**References**


**PEDCD-3.1: Heart Murmur General**

- Heart murmurs are extremely common in pediatric patients. The thinner chest wall in children allows clearer auscultation of blood flowing through the chambers of the heart, which may result in a murmur on physical exam.

- The majority of murmurs are innocent and do not require further evaluation. More than 30% of children may have an innocent murmur detected during physical examination. Innocent murmurs are typically systolic ejection murmurs with a vibratory or musical quality, and generally change in quality when the patient changes position.

- Other types of murmurs can be pathologic and require additional evaluation, usually by a pediatric cardiologist. Echocardiography is indicated, and is performed as part of the office visit. When evaluating a patient with a murmur for the first time, it will not be known whether the patient has congenital heart disease or not. The cardiologist only submits charges for the procedure actually performed.

- The following echocardiography code combinations should be approved for evaluation of any pathologic murmur or any innocent murmur with associated cardiac signs or symptoms:
  - CPT® 93303, CPT® 93306, CPT® 93320, and CPT® 93325
  - CPT® 93303, CPT® 93306
  - CPT® 93306, CPT® 93320 and CPT® 93325 are included with CPT® 93306 and should not be approved separately.

- Repeat echocardiography is not indicated if the initial echocardiogram was normal and the murmur has not changed in quality.

**References**

PEDCD-4.1: Chest Pain General

Chest pain in pediatric patients is caused by a cardiac etiology in < 5% of cases, yet causes great anxiety for parents resulting in requests for testing.

- A recent (within 60 days) face-to-face evaluation including a detailed history, physical examination, EKG, and appropriate laboratory studies should be performed prior to considering advanced imaging.

- Echocardiography is indicated for pediatric patients with chest pain and one or more of the following:
  - Exertional chest pain
  - Non-exertional chest pain with abnormal EKG
  - Chest pain with signs or symptoms of pericarditis
  - First-degree relative with sudden unexplained death or cardiomyopathy
  - Recent onset of fever
  - Recent illicit drug use
  - Other signs or symptoms of cardiovascular disease

- Echocardiography is performed as part of the office visit. When evaluating a patient for the first time, it will not be known whether the patient has congenital heart disease or not. The cardiologist only submits charges for the procedure actually performed.

- The following echocardiography code combinations should be approved for evaluation of chest pain:
  - CPT® 93303, CPT® 93306, CPT® 93320, and CPT® 93325
  - CPT® 93303, CPT® 93306
  - CPT® 93306
  - CPT® 93320 and CPT® 93325 are included with CPT® 93306 and should not be approved separately.

- Repeat echocardiography is not indicated if the initial echocardiogram is normal unless one of the following conditions is present:
  - Increased severity or change in quality of the chest pain
  - New signs or symptoms of cardiovascular disease other than pain
  - New abnormality on EKG

- Cardiac MR is indicated for chest pain if prior evaluation suggests any coronary artery abnormalities, cardiomyopathy, myocarditis or aortic dissection. Cardiac MR with stress should be approved if ischemia is suggested on prior evaluation.
References
**PEDCD-5.1: Syncope**

Syncope in pediatric patients is common, with up to 15% of patients experiencing at least one episode by age 21. Syncope is caused by neurocardiogenic syndrome (vasovagal syncope) in 75 to 80% of cases, which is a benign and self-limiting condition. Despite this, syncope causes great anxiety for parents resulting in requests for testing.

- A recent (within 60 days) face-to-face evaluation including a detailed history, physical examination, EKG, and appropriate laboratory studies should be performed prior to considering advanced imaging.
- Echocardiography is not indicated for most patients with isolated syncope.
- Echocardiography is indicated for pediatric patients with syncope and one or more of the following:
  - Exertional syncope
  - Unexplained post-exertional syncope
  - Abnormal EKG
  - First-degree relative with any of the following before age 50:
    - Sudden cardiac arrest or death
    - Pacemaker or implantable defibrillator placement
  - First-degree relative with cardiomyopathy
  - Known congenital heart disease
  - History of Kawasaki disease, or other coronary pathology.
  - Pathologic murmur, irregular rhythm, gallop, or click on physical examination
- Echocardiography is performed as part of the office visit. When evaluating a patient for the first time, it will not be known whether the patient has congenital heart disease or not. The cardiologist only submits charges for the procedure actually performed.
- The following echocardiography code combinations should be approved for evaluation of syncope:
  - CPT® 93303, CPT® 93306, CPT® 93320, and CPT® 93325
  - CPT® 93303, CPT® 93306
  - CPT® 93306
  - CPT® 93320 and CPT® 93325 are included with CPT® 93306 and should not be approved separately.
- Repeat echocardiography is not indicated if the initial echocardiogram is normal unless one of the following conditions is present:
  - Increased severity or change in quality of the syncope
  - New signs or symptoms of cardiovascular disease other than syncope
  - New abnormality on EKG
- Cardiac MR is indicated for syncope if prior evaluation suggests any coronary artery abnormalities, cardiomyopathy, myocarditis or aortic dissection. Cardiac MR with stress should be approved if ischemia is suggested on prior evaluation.
References
<table>
<thead>
<tr>
<th>PEDCD-6: Kawasaki Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PEDCD-6.1: Kawasaki Disease Initial Imaging</td>
<td>23</td>
</tr>
<tr>
<td>PEDCD-6.2: Acute Phase</td>
<td>23</td>
</tr>
<tr>
<td>PEDCD-6.3: Chronic Phase</td>
<td>25</td>
</tr>
</tbody>
</table>
**PEDCD-6.1: Kawasaki Disease Initial Imaging**

- Kawasaki disease (KD) is the leading cause of acquired pediatric cardiac disease in the developed world. It is an acute febrile illness characterized by a medium vessel vasculitis, which predominantly affects the coronary arteries.
  - A recent (within 60 days) face-to-face evaluation including a detailed history, physical examination, and appropriate laboratory studies should be performed prior to considering advanced imaging.
  - Scheduled indicated follow-up imaging does not require 60 day contact, if indicated based on the below follow-up schedule.
  - Patients who do not fulfill the diagnostic criteria for classic KD may be considered to have incomplete (atypical) KD.
  - If Kawasaki disease is strongly suspected, treatment will often begin even before cardiac evaluation, since early treatment is associated with a lower risk for coronary aneurysm development.

- Echocardiography (CPT® 93306) is indicated for initial assessment for suspected or known Kawasaki disease.
  - Coronary CTA (CPT® 75574), Cardiac MRI without contrast (CPT® 75557), Cardiac MRI without and with contrast (CPT® 75561), or MRA Chest (CPT® 71555) are indicated for evaluation of inconclusive echocardiogram findings, or significant coronary artery abnormalities.
  - Screening of other body areas for aneurysms is not routinely indicated in Kawasaki disease, but MRA or CTA (contrast as requested) of the affected body area can be approved for evaluation of signs or symptoms suggesting aneurysm development.
  - See acute and chronic phase for imaging

**PEDCD-6.2: Acute Phase**

- The acute phase of Kawasaki disease (KD) can last up to 4-6 weeks from the onset of fever until acute systemic inflammation has resolved and coronary artery dimensions are no longer expanding

- Based on AHA recommendations, the following classifications are used in risk stratification of coronary artery abnormalities:
  - Z-Score classification accounts for the effects of body size and age through use of baseline coronary dimensions adjusted for body surface area. The Z score value represents the number of standard deviation above the mean. (e.g., z=0 pt. has coronary artery dimension value equal to mean, z=2 person has value 2 standard deviation above the mean, based on age, gender, BSA).
  - Coronary Artery Abnormalities Risk Classification based on Z-Score:
    1. No involvement at any time point (Z score always <2)
    2. Dilation only (Z score 2 to <2.5)
    3. Small aneurysm (Z score ≥2.5 to <5)
       - 3.1 - Current or persistent
       - 3.2 - Decreased to dilation only or normal luminal dimension
4 - Medium aneurysm (Z score ≥5 to <10, and absolute dimension <8 mm)
   ▪ 4.1 - Current or persistent
   ▪ 4.2 - Decreased to small aneurysm
   ▪ 4.3 - Decreased to dilation only or normal luminal dimension

5 - Large and giant aneurysm (Z score ≥10, or absolute dimension ≥8 mm)
   ▪ 5.1 - Current or persistent
   ▪ 5.2 - Decreased to medium aneurysm
   ▪ 5.3 - Decreased to small aneurysm
   ▪ 5.4 - Decreased to dilation only or normal luminal dimension

Additional Clinical Features That May Increase the Long-Term Risk of Myocardial Ischemia
   ▪ Greater length and distal location of aneurysms that increase the risk of flow stasis
   ▪ Greater total number of aneurysms
   ▪ Greater number of branches affected
   ▪ Presence of luminal irregularities
   ▪ Abnormal characterization of the vessel wall (calcification, luminal myofibroblastic proliferation)
   ▪ Presence of functional abnormalities (impaired vasodilation, impaired flow reserve)
   ▪ Absence or poor quality of collateral vessels
   ▪ Previous revascularization performed
   ▪ Previous coronary artery thrombosis
   ▪ Previous myocardial infarction
   ▪ Presence of ventricular dysfunction


Echocardiography should be performed when the diagnosis of KD is considered,
   ▶ Uncomplicated patients, echocardiography can be repeated after treatment both:
      ▪ Within 1 to 2 weeks
      ▪ Within 4 to 6 weeks
   ▶ For patients with important and evolving coronary artery abnormalities (Z score >2.5) detected during the acute illness, more frequent echocardiography (at least twice per week) should be performed until luminal dimensions have stopped progressing to determine the risk for and presence of thrombosis.
   ▶ Expanding large or giant aneurysms:
      ▪ Twice per week while dimensions are expanding rapidly
      ▪ Once weekly after dimension is stabilized for the first 45 days of illness
      ▪ Then monthly until the third month after illness onset
It is reasonable to obtain advanced imaging studies such as computed tomographic angiography (CTA), cardiac magnetic resonance imaging (CMRI), or invasive angiography on patients’ severe proximal coronary artery abnormalities in the acute phase when results will impact management decisions.

Transesophageal echocardiography, invasive angiography, CMRI, and CTA can be of value in the assessment of selected patients but are not routinely indicated for diagnosis and management of the acute illness.

- Invasive angiography is rarely performed during the acute illness.
  - Transesophageal echocardiography, CTA, and CMRI can be useful for the evaluation of older children and adolescents in whom visualization of the coronary arteries with transthoracic echocardiography is inadequate and results will impact immediate management decisions.
  - These requests will be forwarded to Medical Director for evaluation

Evaluation of potential aneurysmal involvement in other arterial beds can be assessed with CMRI, CTA, and, rarely, invasive angiography after recovery from the acute illness for patients with severe coronary artery involvement or symptoms or signs, such as the presence of a pulsatile axillary mass. All other requests during the acute phase will be forwarded for review.

Atypical or incomplete Kawasaki. Echo is indicated when atypical KD is being considered, may require repeat echocardiograms if treatment decisions will be affected by results (e.g., treating with ivig), if new signs or symptoms (such as typical peeling) develop.

**PEDCD-6.3: Chronic Phase**

- Long-term management begins at the end of the acute illness, usually at 4 to 6 weeks after fever onset. Management is based on two pieces of data:
  - The dimensions of the largest Aneurysm at any point during the disease
  - The dimensions of the largest current aneurysm

- Additional risk factors that may be considered for imaging
  - Greater length and distal location of aneurysms that increase the risk of flow stasis
  - Greater total number of aneurysms
  - Greater number of branches affected
  - Presence of luminal irregularities
  - Abnormal characterization of the vessel wall (calcification, luminal myofibroblastic proliferation)
  - Presence of functional abnormalities (impaired vasodilation, impaired flow reserve)
  - Absence or poor quality of collateral vessels
  - Previous revascularization performed
  - Previous coronary artery thrombosis
  - Previous myocardial infarction
  - Presence of ventricular dysfunction
Long term routine surveillance in asymptomatic imaging for Kawasaki disease—see chart

<table>
<thead>
<tr>
<th>AHA risk level</th>
<th>Largest Aneurysm At Any Point</th>
<th>Largest Current Aneurysm</th>
<th>Routine Echo</th>
<th>Routine Stress Imaging</th>
<th>Routine Coronary Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td></td>
<td></td>
<td>All risk levels 4-6 weeks after acute illness</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>1</td>
<td>Normal</td>
<td>Normal</td>
<td>one echo 2-12 months after acute illness</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>2</td>
<td>Dilation</td>
<td>Dilation</td>
<td>6 months One year If dilation remains echo every 2-5 yrs until resolves.</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>3.1</td>
<td>Small</td>
<td>Small</td>
<td>6 months 12 months then yearly</td>
<td>2-3 years</td>
<td>3-5 years</td>
</tr>
<tr>
<td>3.2</td>
<td>Small</td>
<td>Normal or dilated</td>
<td>6 months 12 months then yearly</td>
<td>3-5 years</td>
<td>none</td>
</tr>
<tr>
<td>4.1</td>
<td>Medium</td>
<td>Medium</td>
<td>3 months 6 months 12 months every 6-12 months after that</td>
<td>1-3 years</td>
<td>2-5 years</td>
</tr>
<tr>
<td>4.2</td>
<td>Medium</td>
<td>Small</td>
<td>6 months and 12 months, every 1 year.</td>
<td>2-3 years</td>
<td>3-5 years</td>
</tr>
<tr>
<td>4.3</td>
<td>Medium</td>
<td>Normal Or Dilated</td>
<td>every 1-2 yrs</td>
<td>2-4 years</td>
<td>none</td>
</tr>
<tr>
<td>5.1</td>
<td>Large</td>
<td>Large</td>
<td>1 month 3 months 6 months 9 months 12 months then every 3-6 months</td>
<td>6-12 months</td>
<td>at 2-6 months, every 1-5 years</td>
</tr>
<tr>
<td>5.2</td>
<td>Large</td>
<td>Medium</td>
<td>every 6-12 months</td>
<td>yearly</td>
<td>2-5 years</td>
</tr>
<tr>
<td>5.3</td>
<td>Large</td>
<td>Small</td>
<td>6-12 month</td>
<td>1-2 years</td>
<td>2-5 years</td>
</tr>
<tr>
<td>5.4</td>
<td>Large</td>
<td>Normal Or Dilation</td>
<td>1-2 years</td>
<td>2-5 years</td>
<td>none</td>
</tr>
</tbody>
</table>
Symptomatic patients

- Echocardiogram can be performed at any time with new or progressing cardiac symptoms
- Stress imaging when there are new or progressing symptoms of ischemia or ventricular dysfunction
- Invasive or coronary imaging Coronary angiography (CT, MRI, invasive) when the above studies are Positive, inconclusive, or otherwise lead to a conclusion that intervention is needed


References
PEDCD-7.0: Pediatric Pulmonary Hypertension General

- Pulmonary hypertension in children can be caused by cardiac, pulmonary, or systemic diseases, and idiopathic disease occurs as well.

- A recent (within 60 days) face-to-face evaluation including a detailed history, physical examination, and appropriate laboratory studies should be performed prior to considering advanced imaging.

- If pulmonary hypertension is suspected, initial evaluation should consist of chest x-ray, EKG, and echocardiography (CPT® 93306, or CPT® 93303, with CPT® 93320, and CPT® 93325, see: PEDCD-8.1: Transthoracic Echocardiography (TTE) Coding for echocardiography coding considerations).

- Repeat echocardiography intervals are variable depending on age of patient, etiology, and severity.
  - After a comprehensive initial evaluation, echocardiograms using PH-specific protocols may be performed every 4 to 6 months.
  - Echocardiography is indicated at any time for new or worsening symptoms or to evaluate a recent change in therapy.
  - Right heart and/or left heart catheterization may be utilized for PAH patients, including before and after initiation of PAH-targeted therapy, and for patients with concomitant congenital heart disease

- Chest CT (CPT® 71250) may be indicated in addition to Chest CTA (CPT® 71275) or Chest MRA (CPT® 71555) for initial evaluation of all pediatric patients with pulmonary hypertension to evaluate for pulmonary vascular or interstitial disease, or other intrathoracic causes.

- Cardiac MRI without and with contrast (CPT® 75561) is indicated for evaluation of inconclusive echocardiogram findings, or for monitoring right ventricular function during follow-up.

- Stress echocardiograms may be indicated (as in adult guidelines) see CD-2.7: Stress Echocardiography – Indications, other than ruling out CAD.
References
<table>
<thead>
<tr>
<th>PEDCD-8: Echocardiography – Other Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEDCD-8.1: Transthoracic Echocardiography (TTE) Coding</td>
</tr>
<tr>
<td>PEDCD-8.2: Initial Transthoracic Echocardiography (TTE) Indications</td>
</tr>
<tr>
<td>PEDCD-8.3: Repeat Transthoracic Echocardiography Indications</td>
</tr>
<tr>
<td>PEDCD-8.4: Transesophageal Echocardiography (TEE)</td>
</tr>
</tbody>
</table>
PEDCD-8.1: Transthoracic Echocardiography (TTE) Coding

- CPT® codes for echocardiography are listed in PEDCD-1: General Guidelines

<table>
<thead>
<tr>
<th>Echocardiogram coding Notes</th>
<th>CPT®</th>
</tr>
</thead>
</table>
| The most commonly performed study is a complete transthoracic echocardiogram with spectral and color flow Doppler (CPT® 93306).
  ◦ CPT® 93306 includes CPT® 93320 and CPT® 93325, so those codes should not be approved along with CPT® 93306. | 93306 |
| Doppler codes (CPT® 93320, CPT® 93321, and CPT® 93325) are add-on codes and are assigned in addition to code for the primary procedure, and should not be approved alone. | +93320 +93321 +93325 |
| For a 2D transthoracic echocardiogram without Doppler, report CPT® 93307. | 93307 |
| A limited transthoracic echocardiogram is reported with CPT® 93308.
  ◦ Limited transthoracic echocardiogram should be billed if the report does not “evaluate or document the attempt to evaluate” all of the required structures.
  ◦ Unlike CPT® 93306, the Doppler CPT® 93321 and CPT® 93325 are not included with CPT® 93308.
  ◦ CPT® 93321 (not CPT® 93320) should be reported with CPT® 93308 if Doppler is included in the study.
  ◦ CPT® 93325 should also be reported with CPT® 93308 if color flow Doppler is included in the study. | 93308 |
| For patients with known congenital heart disease, a limited transthoracic echocardiogram is reported with CPT® 93304, +/- CPT® 93321 and CPT® 93325. | 93304 |

- Providers performing an initial echo on a pediatric patient will not know what procedure codes they will be reporting until the initial study is completed.
  ◦ If congenital heart disease is found on the initial echo, a complete echo is reported with codes CPT® 93303, CPT® 93320, and CPT® 93325 because CPT® 93303 does NOT include Doppler and color flow mapping.
  ◦ If no congenital issue is discovered, then CPT® 93306 is reported alone and includes 2-D, Doppler and color flow mapping.

- Since providers may not know the appropriate code/s that will be reported at the time of the pre-authorization request, they may request multiple codes.
  ◦ The following echocardiography code combinations should be approved for any initial echocardiogram:
    - CPT® 93303, CPT® 93306, CPT® 93320, and CPT® 93325
    - CPT® 93303, CPT® 93306
    - CPT® 93306
      ◦ CPT® 93320 and CPT® 93325 are included with CPT® 93306 and should not be approved separately.
  ◦ Depending upon individual health plan payer contracts, post-service audits may be completed to ensure proper claims submission.
PEDCD-8.2: Initial Transthoracic Echocardiography (TTE) Indications

- In addition to indications listed in previous guideline sections, initial TTE evaluation is indicated for any of the following:
  - Any signs/symptoms that are possibly cardiac in nature, including (but not limited to) central cyanosis, dyspnea, edema, poor peripheral pulses, feeding difficulty, decreased urine output, hepatomegaly, or desaturation on pulse oximetry.
  - Abnormal EKG or cardiac biomarkers
  - Abnormal chest x-ray suggesting cardiovascular disease
  - Palpitations and one of the following:
    - Abnormal EKG
    - First-degree relative with any of the following before age 50:
      - Sudden cardiac arrest or death
      - Pacemaker or implantable defibrillator placement
    - First-degree relative with cardiomyopathy
  - Supraventricular Tachycardia (SVT), Ventricular Tachycardia, or Premature Ventricular Contractions (PVCs)
  - Known or suspected valvular dysfunction
  - Persistent systemic hypertension
  - Obesity (BMI > 30) with additional cardiovascular risk factors
  - Stroke
  - Renal failure
  - Preoperative evaluation of patients with chest wall deformities or scoliosis
  - Known or suspected vascular ring
  - Planned administration of cardiotoxic chemotherapy
    - Generally anthracyclines (doxorubicin, daunorubicin, mitoxantrone, idarubicin, epirubicin)
  - Planned radiation therapy involving heart muscle or hematopoietic stem cell transplant
  - Sickle cell disease or other hemoglobinopathy causing chronic anemia
  - Known or suspected vasculitis, acute rheumatic fever, or other systemic autoimmune disease
  - Muscular dystrophy
  - Metabolic, mitochondrial, and storage disorders
  - Abnormalities of cardiac or other viscera situs
  - Signs, symptoms, or blood culture suggestive of endocarditis
  - Known or suspected mass lesion involving the heart or great vessels
  - Known or suspected clot in atrium or ventricle
  - Known or suspected pulmonary hypertension
  - Known or suspected pericardial effusion
  - Complications during prenatal development:
    - Known or suspected cardiovascular abnormality on fetal echocardiogram
    - Maternal phenylketonuria (PKU)
    - Maternal diabetes with no fetal echo
    - Maternal teratogen exposure
    - Maternal infection during pregnancy with potential cardiac sequelae
Genetic abnormality known to be associated with cardiovascular disease
First-degree relative family history of:
- Unexplained sudden death before age 50
- Hypertrophic cardiomyopathy
- Non-ischemic dilated cardiomyopathy
- Genetic abnormality known to be associated with cardiovascular disease
- Congenital left-sided heart lesion
- Heritable pulmonary arterial hypertension

PEDCD-8.3: Repeat Transthoracic Echocardiography Indications
- Repeat echocardiograms may be required for patients with no new symptoms.
- In addition to indications listed in previous guideline sections, repeat TTE evaluation is indicated for any of the following:
  - New or worsening symptoms in a patient with known cardiac disease, previously normal echocardiogram with one of the following:
    - New or worsening cardiac symptoms
    - New EKG abnormality
    - Newly recognized family history suggestive of heritable heart disease
  - Every 12 months for patients age 12 to 18 years with first-degree family history of hypertrophic cardiomyopathy.
  - Patients who are status post heart transplant can have echocardiograms repeated as often as requested by heart transplant team.
  - Every 12 months for patients receiving active therapy for ventricular hypertrophy, valvular dysfunction, cardiomyopathy.
    - One time repeat TTE can be approved at 6 months to assess response to a change in therapy.
  - Every 12 months for patients with chronic pericardial effusions
  - Every 12 months for sickle cell disease or other hemoglobinopathy causing chronic anemia and one of the following:
    - High risk genotype (Hgb SS or Sβ0, severe thalassemia, etc.)
    - History of acute chest syndrome or intrinsic lung disease
    - History of stroke
    - Receiving chronic transfusion therapy
  - As needed for monitoring cardiotoxicity during chemotherapy administration
  - After completion of chemotherapy and/or radiation therapy. See PEDONC-19.2: Cardiotoxicity and Echocardiography for imaging guidelines.

PEDCD-8.4: Transesophageal Echocardiography (TEE)
- Transesophageal echocardiography imaging indications in pediatric patients are identical to those for adult patients. See CD-2.5: Transesophageal Echocardiography (TEE) – Indications in the Cardiac Imaging Guidelines.
References


<table>
<thead>
<tr>
<th>PEDCD-9: Cardiac MRI – Other Indications</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PEDCD-9.1: Cardiac MRI General Guidelines</td>
<td>37</td>
</tr>
<tr>
<td>PEDCD-9.2: Cardiac MRI Coding</td>
<td>37</td>
</tr>
<tr>
<td>PEDCD-9.3: Indications for Cardiac MRI</td>
<td>37</td>
</tr>
<tr>
<td>PEDCD-9.4: Aortic Root and Aorta</td>
<td>39</td>
</tr>
<tr>
<td>PEDCD-9.5: Evaluation of Pericardial Effusion or Diagnosis of Pericardial Tamponade</td>
<td>39</td>
</tr>
</tbody>
</table>
PEDCD-9.1: Cardiac MRI General Guidelines

- Requests for cardiac MRI that contain only one CPT® code can be completed by the Nurse Reviewer. If the request contains more than one cardiac/chest MRI CPT® code, it should be forwarded for Medical Director Review.

PEDCD-9.2: Cardiac MRI Coding

<table>
<thead>
<tr>
<th>Cardiac Imaging Procedure Codes</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast.</td>
<td>75557</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without and with contrast and further sequences.</td>
<td>75561</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast; with stress imaging (rarely used in pediatrics).</td>
<td>75559</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without and with contrast and further sequences; with stress imaging (rarely used in pediatrics).</td>
<td>75563</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure).</td>
<td>+75565</td>
</tr>
</tbody>
</table>

- Only one procedure code from the set: CPT® 75557, CPT® 75559, CPT® 75561, and CPT® 75563 should be reported per session.

- Only one flow velocity measurement (CPT® +75565) should be reported per session.

PEDCD-9.3: Indications for Cardiac MRI

- In addition to indications listed in previous guideline sections, Cardiac MRI evaluation is indicated for any of the following, when a recent TTE is inconclusive:
  - Assessment of global ventricular function and mass if a specific clinical question is left unanswered by recent TTE and the MRI results will affect the management of the patient’s condition
  - Patients with complex congenital heart disease (e.g. Tetralogy of Fallot [TOF], single ventricle, truncus arteriosis, Transposition of the Great Arteries [TGA]) may require a baseline MRI, or routine cardiac MRI, especially as they approach their teenage years, due to poor imaging windows on echocardiogram, and the need for specific clinical information not seen on prior echocardiograms due to these known limitations, and these studies should be forwards to the medical director. Once these patients reach age 18, they can be imaging by adult congenital heart disease guideline.
  - Clinical suspicion of arrhythmogenic right ventricular dysplasia (ARVD) or arrhythmogenic cardiomyopathy (ARVC).
  - For pericardial disease (including constrictive pericarditis, restrictive pericarditis, and perimyocarditis), MRI should not be utilized to diagnose pericarditis but only to answer the question regarding possible constriction or restriction suggested clinically or by other techniques (TTE, etc.)
- MRI without and with contrast (CPT® 75561) is considered the optimal test for this disorder.
  - Evaluate cardiac tumor or mass
    - MRI without and with contrast (CPT® 75561) is considered the optimal test for this disorder.
  - Evaluate anomalous coronary artery
    - After echocardiogram, MRI without and with contrast (CPT® 75561) or CCTA (CPT® 75574) is considered the optimal test for this disorder.
  - For Fabry’s disease, late enhancement MRI may predict the effect of enzyme replacement therapy on myocardial changes that occur with this disease.
    - MRI without and with contrast (CPT® 75561) is considered the preferred test for this disorder.
  - Cardiac MRI can be performed to evaluate patients with congenital cardiomyopathy (muscular dystrophy, glycogen storage disease, fatty acid oxidation disorders, mitochondrial disorders, etc.) or unexplained cases of cardiomyopathy in order to characterize the myocardium.
  - Cardiac stress perfusion study (CPT® 75559 or CPT® 75563) can be considered on a case by case basis for patients with any of the following:
    - Anomalous coronary artery
    - Kawasaki disease
    - TGA
    - Ross operation
    - or other disorder with the potential for coronary ischemia
    - Patients in whom an exercise stress test (EST) without imaging is indicated, but they cannot perform
    - Patients in whom an exercise stress test (EST) is equivocal, positive, or concern for a false negative
  - Assessment of cardiac iron overload such as in hemochromatosis, thalassemia, sickle cell (either CPT® 75557 or CPT® 71550, T2* MRI, contrast not necessary).
    - Screening imaging may be approved every 12 months
    - Imaging may be approved every 3 months for treatment response in patients receiving active treatment (chelation +/- phlebotomy)
    - Frequently performed along with MRI Abdomen (CPT® 74181) to assess liver iron deposition. See PEDAB-18.2: Transfusion-Associated (Secondary) Hemochromatosis for additional imaging guidelines.
PEDCD-9.4: Aortic Root and Aorta

- For screening due to family history of aortic aneurysm or dissection, see: PVD-2.2: Screening for Vascular related genetic connective tissue Disorders (Familial Aneurysm Syndromes/Spontaneous Coronary Artery Dissection (SCAD)/Ehlers-Danlos/Marfan/Loeys-Dietz).

- For patients who have both cardiac and ascending aorta abnormalities (e.g., truncus arteriosus), the following studies may be indicated following TTE:
  - Cardiac MRI (CPT® 75557 or CPT® 75561) when TTE is inconclusive.
  - If aorta is involved, MRI Chest (CPT® 71552) or MRA Chest (CPT® 71555) is also indicated.

- For patients with aortic abnormalities without cardiac abnormalities, any of the following studies is indicated:
  - MRI Chest (CPT® 71552)
  - MRA Chest (CPT® 71555)

PEDCD-9.5: Evaluation of Pericardial Effusion or Diagnosis of Pericardial Tamponade

- Echocardiogram is the initial imaging study of choice to evaluate pericardial effusions or diagnose pericardial tamponade.

- If a specific clinical question is left unanswered by another recent imaging study and the answer to the clinical question will affect the management of the patient’s clinical condition, contrast-enhanced cardiac MRI is useful for evaluating:
  - Pericarditis
  - Neoplastic effusion
  - Tamponade
  - Myocardial infiltration.

- Cancers that can metastasize to the pericardium or myocardium and can cause a malignant effusion include lung, breast, renal cell, lymphoma and melanoma.
References


## PEDCD-10: CT Heart and Coronary Computed Tomography Angiography (CCTA) – Other Indications

| PEDCD-10.1: CT Heart and Coronary Computed Tomography Angiography (CCTA) General Considerations | 42 |
| PEDCD-10.2: Anomalous Coronary Artery | 42 |
| PEDCD-10.3: Indications for CCTA (CPT® 75574) | 43 |
| PEDCD-10.4: Indications for Cardiac CT (CPT® 75572) | 43 |
| PEDCD-10.5: Radiation Dose | 44 |
PEDCD-10.1: CT Heart and Coronary Computed Tomography Angiography (CCTA) General Considerations

- Metal artifact reduces the accuracy of CCTA. Devices that can cause this issue include, but are not limited to, surgical clips, pacemaker devices, defibrillator devices, and tissue expanders.
- Cardiac testing that does not involve exposure to ionizing radiation should be strongly considered.

**Practice Note**

**Relative Contraindications to CCTA Include:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very obese patients (body mass index &gt; 40 kg/m²)</td>
<td></td>
</tr>
<tr>
<td>Elevated calcium score: CCTA should not be performed if there is extensive coronary calcification (calcium score &gt;1000).</td>
<td></td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td></td>
</tr>
<tr>
<td>Inability to follow breath-holding instructions</td>
<td></td>
</tr>
</tbody>
</table>

PEDCD-10.2: Anomalous Coronary Artery

- Evaluating coronary artery anomalies and other complex congenital heart disease of cardiac chambers or great vessels is an appropriate indication for CCTA, or cardiac MRI
  - Report CPT® 75574 for evaluating coronary artery anomalies
  - Report CPT® 75573 for congenital heart disease
  - Can add CPT® 71275 (chest CTA) to evaluate great vessels

- Congenital anomalies of the coronary arteries are an important cause of sudden death in pediatric patients. Coronary arteries may arise from the wrong coronary artery cusp leading to ischemic changes during exercise. These lesions may be found incidentally during a murmur evaluation. Anomalous coronary arteries may be seen on echocardiogram during an evaluation for chest pain or syncope or palpitations. In addition patients with no echocardiographic findings, but symptoms concerning for angina chest pain may require stress testing. Patients who have positive echocardiographic findings, regardless of symptoms, and patients who have classical typical angina chest pain regardless of echocardiographic findings, may require treadmill stress testing, stress imaging, of advanced imaging such as Cardiac MRI, Stress echocardiogram, PET, Cardiac CT, and/or cardiac catheterization.

- Patients with congenital heart disease such as TOF, Truncus Arteriosus, and TGA have increased incidence of coronary artery anomalous and may require the above imaging as well

- Patients with confirmed coronary artery anomalies may require repeat imaging based on the clinical scenario
The use of CCTA to rule out anomalous coronary artery should be limited to one of the following:
- Patients who need to have an anomalous coronary artery mapped prior to an invasive procedure.
- Patients who have not had a previous imaging study that clearly demonstrates an anomalous coronary artery.
- Patients with a history that includes one or more of the indications in PEDCD-10.3: Indications for CCTA (CPT® 75574).

PEDCD-10.3: Indications for CCTA (CPT® 75574)

In addition to indications listed in previous guideline sections, CCTA is indicated for any of the following, when a recent TTE and/or MRI is inconclusive:
- Persistent exertional chest pain and normal stress test.
- Full sibling(s) with history of sudden death syndrome before age 30 or with documented anomalous coronary artery.
- Resuscitated sudden death and contraindication to conventional coronary angiography.
- Unexplained new onset of heart failure if CCTA will replace conventional invasive coronary angiography.
- Documented ventricular tachycardia (6 beat runs or greater) if CCTA will replace conventional invasive coronary angiography.
- Equivocal coronary artery anatomy on conventional cardiac catheterization.
- In infants: otherwise unexplained dyspnea, tachypnea, wheezing, episodic pallor, irritability, sweating, poor feeding, and/or failure to thrive.
  - The presence of other congenital heart disease is not a separate indication for CCTA to rule out anomalous coronary artery (except when coronary artery surgery is pending, i.e. Transposition of the great arteries, Tetralogy of Fallot, Truncus arteriosus, aortic root surgery).
- Evaluation of the arterial supply and venous drainage in children with bronchopulmonary sequestration.

PEDCD-10.4: Indications for Cardiac CT (CPT® 75572)

In addition to indications listed in previous guideline sections, CCTA is indicated for any of the following, when a recent TTE and/or MRI is inconclusive:
- Cardiac or pericardial mass.
- Pericarditis.
- Complications of cardiac surgery or evaluation of post-operative anatomy.
- Cardiac thrombus in patients with technically limited TTE, TEE, or MRI.
- Clinical suspicion of arrhythmogenic right ventricular dysplasia (ARVD) or arrhythmogenic cardiomyopathy (ARVC).
- Native aortic abnormalities if echocardiogram is indeterminate.
**PEDCD-10.5: Radiation Dose**

- ACR–NASCI–SPR Practice Parameter For The Performance And Interpretation Of Cardiac Computed Tomography (CT) states “Cardiac CT should be performed only for a valid medical indication and with the minimum radiation exposure that provides diagnostic image quality”

- ACR–NASCI–SPR Practice Parameter for the Performance of Quantification of Cardiovascular Computed Tomography (CT) And Magnetic Resonance Imaging (MRI) states “In younger patients, MRI may be the preferred modality, particularly when functional assessment with CT would require retrospective ECG gating and relatively high radiation doses. Further, the use of time-resolved MRA and phase contrast MRI methods offer significant advantages whose relative importance will depend on the specific application”

- See table: Practice Estimate of Effective Radiation Dose chart for Selected Imaging Studies in **CD-1: General Guidelines**

**References**


<table>
<thead>
<tr>
<th>PEDCD-11: Cardiac Catheterization</th>
</tr>
</thead>
<tbody>
<tr>
<td>PEDCD-11.1: Cardiac Catheterization General Information</td>
</tr>
<tr>
<td>PEDCD-11.2: Cardiac Catheterization Indications</td>
</tr>
</tbody>
</table>
# PEDCD-11.1: Cardiac Catheterization General Information

<table>
<thead>
<tr>
<th>Cardiac Cath Procedures</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital Heart Disease Code “Set”</td>
<td>93530-93533</td>
</tr>
<tr>
<td>Right Heart Catheterization (CHD)</td>
<td>93530</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CHD)</td>
<td>93531</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CHD-TS)</td>
<td>93532</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CAD-ASD)</td>
<td>93533</td>
</tr>
<tr>
<td>Anomalous coronary arteries, patent foramen ovale, mitral valve prolapse, and bicuspid aortic valve</td>
<td>93451-93464, 93566-93568</td>
</tr>
<tr>
<td>RHC without LHC or coronaries</td>
<td>93451</td>
</tr>
<tr>
<td>LHC without RHC or coronaries</td>
<td>93452</td>
</tr>
<tr>
<td>RHC and retrograde LHC without coronaries</td>
<td>93453</td>
</tr>
<tr>
<td>Native coronary artery catheterization; with bypass grafts</td>
<td>93454</td>
</tr>
<tr>
<td>with RHC</td>
<td>93455</td>
</tr>
<tr>
<td>with RHC and bypass grafts</td>
<td>93456</td>
</tr>
<tr>
<td>with LHC</td>
<td>93457</td>
</tr>
<tr>
<td>with LHC and bypass grafts</td>
<td>93458</td>
</tr>
<tr>
<td>with RHC and LHC</td>
<td>93459</td>
</tr>
<tr>
<td>with RHC and LHC and bypass grafts</td>
<td>93460</td>
</tr>
<tr>
<td>LHC by trans-septal or apical puncture</td>
<td>93461</td>
</tr>
<tr>
<td>Angiography of non-coronary arteries and veins performed as a distinct service</td>
<td>Select appropriate codes from the Radiology and Vascular Injection Procedures sections.</td>
</tr>
</tbody>
</table>

Select appropriate codes from the Radiology and Vascular Injection Procedures sections.

CPT® 93530 to 93533 are appropriate for invasive evaluation of congenital heart disease.

- These guidelines apply to individuals with stable conditions and who are not in the acute setting. Individuals in acute settings or with unstable angina should be handled as medical emergencies.

- Pediatric catheterizations are done for many purposes, including diagnosis and intervention of congenital and acquired heart disease.

- When device placement is planned (ASD/VSD device, transcatheter valve implantation, pda device), the procedure codes for those devices include all cardiac catheterization(s), intraprocedural contrast injection(s), fluoroscopic radiological supervision and interpretation, and imaging guidance performed to complete the procedure. For coarctation or aortic arch stenting, or other endovascular procedures with no intracardiac issues that require clarification by left heart cath, a left heart cath is not required along with these endovascular procedures. A right heart cath can be approved for pulmonary artery interventions (e.g., stents, coils).
PEDCD-11.2: Cardiac Catheterization Indications

Diagnostic catheterization is indicated:
- When other advanced imaging has failed to resolve a clinical issue and results will impact patient management
- For preoperative assessment in complex heart disease
  - Norwood procedure
  - Bidirectional Glenn shunt
  - Fontan procedure
  - Pulmonary atresia
- Pulmonary hypertension
- With some interventions such as:
  - Valvuloplasty
  - Stents
- See PEDCD-6.1: Kawasaki Disease Initial Imaging for specific intervals in Kawasaki Disease
- On a patient who is having a device placed when:
  - A diagnostic catheterization, or stenting is needed in addition to the device
  - The diagnostic catheterization is indicated separate from the device placement

References
### Procedure Codes Associated with Cardiac or PVD Imaging

<table>
<thead>
<tr>
<th>MRI/MRA</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast material</td>
<td>75557</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast material; with stress imaging</td>
<td>75559</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences</td>
<td>75561</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging</td>
<td>75563</td>
</tr>
<tr>
<td>Cardiac magnetic resonance imaging for velocity flow mapping (List separately in addition to code for primary procedure)</td>
<td>75565</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CT</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium</td>
<td>75571</td>
</tr>
<tr>
<td>Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)</td>
<td>75572</td>
</tr>
<tr>
<td>Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)</td>
<td>75573</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission, analysis of fluid dynamics and simulated maximal coronary hyperemia, generation of estimated FFR model, with anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report</td>
<td>0501T</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission</td>
<td>0502T</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and generation of estimated FFR model</td>
<td>0503T</td>
</tr>
<tr>
<td>Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report</td>
<td>0504T</td>
</tr>
</tbody>
</table>
### CTA

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)</td>
<td>75574</td>
</tr>
<tr>
<td>Computed tomographic angiography, abdominal aorta and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed, and image postprocessing</td>
<td>75635</td>
</tr>
</tbody>
</table>

### Nuclear Medicine

<table>
<thead>
<tr>
<th>Description</th>
<th>CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determination of central c-v hemodynamics (non-imaging) (eg, ejection fraction with probe technique) with or without pharmacologic intervention or exercise, single or multiple determinations</td>
<td>78414</td>
</tr>
<tr>
<td>Cardiac shunt detection</td>
<td>78428</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), single study; with concurrently acquired computed tomography transmission scan</td>
<td>78429</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); single study, at rest or stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan</td>
<td>78430</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), perfusion study (including ventricular wall motion[s] and/or ejection fraction[s], when performed); multiple studies at rest and stress (exercise or pharmacologic), with concurrently acquired computed tomography transmission scan</td>
<td>78431</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan</td>
<td>78432</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), combined perfusion with metabolic evaluation study (including ventricular wall motion[s] and/or ejection fraction[s], when performed), dual radiotracer (eg, myocardial viability); with concurrently acquired computed tomography transmission scan</td>
<td>78433</td>
</tr>
<tr>
<td>Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)</td>
<td>78434</td>
</tr>
<tr>
<td>Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)</td>
<td>78451</td>
</tr>
<tr>
<td>Myocardial perfusion imaging, tomographic (SPECT) (including attenuation correction, qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection</td>
<td>78452</td>
</tr>
<tr>
<td>Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); single study, at rest or stress (exercise or pharmacologic)</td>
<td>78453</td>
</tr>
<tr>
<td>Procedure Description</td>
<td>CPT Code</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Myocardial perfusion imaging, planar (including qualitative or quantitative wall motion, ejection fraction by first pass or gated technique, additional quantification, when performed); multiple studies, at rest and/or stress (exercise or pharmacologic) and/or redistribution and/or rest reinjection</td>
<td>78454</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), metabolic evaluation study (including ventricular wall motion and/or ejection fraction, when performed), single study</td>
<td>78459</td>
</tr>
<tr>
<td>Myocardial imaging, infarct avid, planar; qualitative or quantitative</td>
<td>78466</td>
</tr>
<tr>
<td>Myocardial imaging, infarct avid, planar; with ejection fraction by first pass technique</td>
<td>78468</td>
</tr>
<tr>
<td>Myocardial imaging, infarct avid, planar; tomographic SPECT with or without quantification</td>
<td>78469</td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium; planar, single study at rest or stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without additional quantitative processing</td>
<td>78472</td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium; multiple studies, wall motion study plus ejection fraction, at rest and stress (exercise and/or pharmacologic), with or without additional quantification</td>
<td>78473</td>
</tr>
<tr>
<td>Cardiac blood pool imaging (planar), first pass technique; single study, at rest or with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification</td>
<td>78481</td>
</tr>
<tr>
<td>Cardiac blood pool imaging (planar), first pass technique; multiple studies, at rest and with stress (exercise and/or pharmacologic), wall motion study plus ejection fraction, with or without quantification</td>
<td>78483</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), perfusion (including ventricular wall motion and/or ejection fraction, when performed); single study at rest or stress (exercise or pharmacologic)</td>
<td>78491</td>
</tr>
<tr>
<td>Myocardial imaging, positron emission tomography (PET), perfusion (including ventricular wall motion and/or ejection fraction, when performed); multiple studies at rest and/or stress (exercise or pharmacologic)</td>
<td>78492</td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium, SPECT, at rest, wall motion study plus ejection fraction, with or without quantitative processing</td>
<td>78494</td>
</tr>
<tr>
<td>Cardiac blood pool imaging, gated equilibrium, single study, at rest, with right ventricular ejection fraction by first pass technique (List separately in addition to code for primary procedure)</td>
<td>78496</td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging Limited area</td>
<td>78800</td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging Multiple areas</td>
<td>78801</td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging Whole Body</td>
<td>78802</td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging SPECT</td>
<td>78803</td>
</tr>
<tr>
<td>Radiopharmaceutical Localization Imaging Whole Body, requiring 2 or more days imaging</td>
<td>78804</td>
</tr>
<tr>
<td>Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment</td>
<td>0331T</td>
</tr>
<tr>
<td>Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT</td>
<td>0332T</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>CPT®</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Transthoracic echocardiography for congenital cardiac anomalies; complete</td>
<td>93303</td>
</tr>
<tr>
<td>Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study</td>
<td>93304</td>
</tr>
<tr>
<td>Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography</td>
<td>93306</td>
</tr>
<tr>
<td>Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, without spectral or color Doppler echocardiography</td>
<td>93307</td>
</tr>
<tr>
<td>Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study</td>
<td>93308</td>
</tr>
<tr>
<td>Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report</td>
<td>93312</td>
</tr>
<tr>
<td>Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); placement of transesophageal probe only</td>
<td>93313</td>
</tr>
<tr>
<td>Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); image acquisition, interpretation and report only</td>
<td>93314</td>
</tr>
<tr>
<td>Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report</td>
<td>93315</td>
</tr>
<tr>
<td>Transesophageal echocardiography (TEE) for congenital cardiac anomalies; placement of transesophageal probe only</td>
<td>93316</td>
</tr>
<tr>
<td>Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only</td>
<td>93317</td>
</tr>
<tr>
<td>Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete</td>
<td>+93320</td>
</tr>
<tr>
<td>Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)</td>
<td>+93321</td>
</tr>
<tr>
<td>Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)</td>
<td>+93325</td>
</tr>
<tr>
<td>Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report;</td>
<td>93350</td>
</tr>
<tr>
<td>Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional</td>
<td>93351</td>
</tr>
<tr>
<td>Use of echocardiographic contrast agent during stress echocardiography (List separately in addition to code for primary procedure)</td>
<td>+93352</td>
</tr>
<tr>
<td>Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)</td>
<td>+93356</td>
</tr>
<tr>
<td>Description</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete</td>
<td>C8921</td>
</tr>
<tr>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study</td>
<td>C8922</td>
</tr>
<tr>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, complete, without spectral or color doppler echocardiography</td>
<td>C8923</td>
</tr>
<tr>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording when performed, follow-up or limited study</td>
<td>C8924</td>
</tr>
<tr>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, real time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report</td>
<td>C8925</td>
</tr>
<tr>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report</td>
<td>C8926</td>
</tr>
<tr>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report</td>
<td>C8928</td>
</tr>
<tr>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography</td>
<td>C8929</td>
</tr>
<tr>
<td>Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision</td>
<td>C8930</td>
</tr>
<tr>
<td>Myocardial contrast perfusion echocardiography, at rest or with stress, for assessment of myocardial ischemia or viability (List separately in addition to code for primary procedure)</td>
<td>+0439T</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac Catheterization Procedure Codes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Right Heart Catheterization (CHD)</td>
<td>93530</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CHD)</td>
<td>93531</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CHD-TS)</td>
<td>93532</td>
</tr>
<tr>
<td>Right/Left Heart Catheterization (CAD-ASD)</td>
<td>93533</td>
</tr>
<tr>
<td>RHC without LHC or coronaries</td>
<td>93451</td>
</tr>
<tr>
<td>LHC without RHC or coronaries</td>
<td>93452</td>
</tr>
<tr>
<td>RHC and retrograde LHC without coronaries</td>
<td>93453</td>
</tr>
<tr>
<td>Native coronary artery catheterization; with bypass grafts</td>
<td>93454</td>
</tr>
<tr>
<td>with RHC</td>
<td>93455</td>
</tr>
<tr>
<td>with RHC and bypass grafts</td>
<td>93456</td>
</tr>
<tr>
<td>with LHC</td>
<td>93457</td>
</tr>
<tr>
<td>with LHC and bypass grafts</td>
<td>93458</td>
</tr>
<tr>
<td>with LHC and bypass grafts</td>
<td>93459</td>
</tr>
<tr>
<td>Description</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>with RHC and LHC</td>
<td>93460</td>
</tr>
<tr>
<td>with RHC and LHC and bypass grafts</td>
<td>93461</td>
</tr>
<tr>
<td>LHC by transseptal or apical puncture</td>
<td>+93462</td>
</tr>
</tbody>
</table>